deziglipel   Click here for help

GtoPdb Ligand ID: 14614

Synonyms: compound 1086 [WO2017175066] | compound 32 [PMID: 41054342] | MKP-10241 | MKP10241
Compound class: Synthetic organic
Comment: Deziglipel is the INN for a G-protein-coupled receptor 119 (GPR119) agonist, as presented in WHO INN Proposed List 135 (July 2026). It is proposed for the treatment of steatohepatitis and type 2 diabetes in this INN record. It is one of the compounds claimed in patents held by Mankind Pharma that are disigned to target the GPR119/incretin axis as a mechanism to treat metabolic disorders [1]. and deziglipel is a structural match for the declared GPR119 clinical lead MKP10241 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 132.97
Molecular weight 530.64
XLogP 2.48
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC1=CN=C(N=C1)N2CCC(CC2)[C@H](C)OC3=NN4C=C(C5=C(C=C(C=C5)S(=O)(=O)C)F)N=C4S3
Isomeric SMILES C(C)C=1C=NC(=NC1)N2CCC(CC2)[C@H](C)OC3=NN4C(S3)=NC(=C4)C5=C(C=C(C=C5)S(=O)(=O)C)F
InChI InChI=1S/C24H27FN6O3S2/c1-4-16-12-26-22(27-13-16)30-9-7-17(8-10-30)15(2)34-24-29-31-14-21(28-23(31)35-24)19-6-5-18(11-20(19)25)36(3,32)33/h5-6,11-15,17H,4,7-10H2,1-3H3/t15-/m0/s1
InChI Key UUMBXZTUKTTYMG-HNNXBMFYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
MKP10241 has been progressed as a clinical candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07098663 Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes Phase 2 Interventional Mankind Pharma Limited